Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease

Ahai Luvai, Wycliffe Mbagaya, Alistair S Hall, Julian H Barth, Ahai Luvai, Wycliffe Mbagaya, Alistair S Hall, Julian H Barth

Abstract

Rosuvastatin is a new generation HMG-CoA reductase inhibitor which exhibits some unique pharmacologic and pharmacokinetic properties. It has low extrahepatic tissue penetration, low potential for CYP3A4 interactions and substantial LDL-C lowering capacity and therefore has distinct advantages. We conducted a Medline literature search to identify rosuvastatin papers published in English. In this review, we outline the pharmacology of rosuvastatin, highlighting its efficacy and safety. We also review the major clinical trials with reference to primary and secondary prevention, familial hypercholesterolaemia and comparison with other statins. Finally we address its place in clinical practice.

Keywords: cardiovascular risk; low density lipoprotein cholesterol; rosuvastatin; statins.

Figures

Figure 1
Figure 1
CHD event rate in primary prevention trials.

References

    1. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ. 1991;303:276–82.
    1. Gordon T, Castelli WI, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease. The Framingham study. Am J Med. 1977;62:707–14.
    1. White CM, et al. A review of HMG CoA reductase inhibitors. US Pharmacist. 1998;23:HS19–28.
    1. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
    1. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatinin type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685–96.
    1. Koren MJ, Hunninghake DB ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J Am Coll Cardiol. 2004;44:72–9.
    1. Durrington PN. Hyperlipidemia: diagnosis and management. 3rd edition. Hodder Arnold; London: 2007.
    1. Alsheikh-Ali A, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation. 2005;111:3051–7.
    1. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.
    1. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs. usual care: the anti-hypertensive and lipid-lowering treatment to prevent heart attack trial ( ALLHAT-LLT) JAMA. 2002;288:2998–3007.
    1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet. 1994;344:1383–9.
    1. Waters DD, Guyton JR, Herrington DM, et al. Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol. 2004;93:154–8.
    1. de Jongh S, Lilien MR, op’t Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117–21.
    1. Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–78.
    1. White CM. A pharmacokinetic comparison of HMG CoA reductase inhibitors. Connecticut Medicine. 2000;64:533–5.
    1. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol. 2002;42:963–70.
    1. AstraZeneca Pharmaceuticals LP. Crestor (rosuvastatin calcium) prescribing information. Wilmington: DE; 2003.
    1. McTaggart F. Comparative pharmacology of rosuvastatin. Atherosclerosis. 2003;4:9–14.
    1. Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science. 2001;11:1160–4.
    1. Buckett L, Ballard P, Davidson R, et al. Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells. Atherosclerosis. 2000;151:41.
    1. Arad Y, Ramakrishnan R, Ginsberg HN. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride- rich lipoproteins. Metabolism. 1992;41:487–93.
    1. Davidson MH, Ma PTS, Stein E, et al. Rosuvastatin is superior to atorvastatin in decreasing low density lipoprotein cholesterol and increasing high-density lipoprotein cholesterol in patients with type IIa or IIb hypercholesterolemia. J Am Coll Cardiol. 2001;37:292. [abstract]
    1. Stein E, Strutt K, Southworth H, et al. Comparison of rosuvastatin versus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol. 2003;92:1287–93.
    1. Caslake MJ, Stewart G, Day SP, et al. Phenotype-dependent and— independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis. 2003;171:245–53.
    1. Brown CDA, Windass A, Bleasby K, et al. The HMG-CoA reductase inhibitor rosuvastatin is a high affinity substrate of the hepatic organic anion transporter OATP-C. Atherosclerosis. 2001;(Suppl 2):90. [abstract].
    1. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28–32.
    1. Grosser N, Erdmann K, Hemmerle A, et al. Rosuvastatin upregulates the antioxidant defense protein heme oxygenase-1. Biochem Biophys Res Commun. 2004;325:871–6.
    1. Mayer C, Gruber HJ, Landl EM, et al. Rosuvastatin reduces interleukin-6-induced expression of C-reactive protein in human hepatocytes in a STAT3- and C/EBP-dependent fashion. Int J Clin Pharmacol Ther. 2007;45:319–27.
    1. Laumen H, Skurk T, Hauner H, et al. The HMG-CoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008;196:565–73.
    1. McTaggart F, Buckett L, Davidson R, et al. Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol. 2001;87:28–32.
    1. Warwick MJ, Dane AL, Raza A, et al. Single and multiple dose pharmacokinetics and safety of the new HMG CoA reductase inhibitor ZD4522. Atherosclerosis. 2000;151:39.
    1. Martin PD, Mitchell PD, Schneck DW. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Br J Clin Pharmacol. 2002;54:472–7.
    1. Martin PD, Warwick MJ, Dane AL, et al. Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers. Clin Ther. 2003;25:2822–35.
    1. Soran H, Durrington P. Rosuvastatin efficacy, safety and clinical effectiveness. Expert Opin Pharmacother. 2008;9(12):2145–60.
    1. Nakamura H, Arakawa K, Itakura H, et al. for the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155–63.
    1. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005;352:20–8.
    1. Ridker PM, Danielson E, Fonseca FAH, et al. for the JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.
    1. Ridker PM, Macfadyen JG, Nordestgaard BG, et al. Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for “intermediate risk”. Circ Cardiovasc Qual Outcomes. 2010;3:447–52.
    1. Koenig W, Ridker PM. Rosuvastatin for primary prevention in patients with European systematic coronary risk evaluation risk ≥5% or Framingham risk ≥ 20%: post hoc analyses of the JUPITER trial requested by European health authorities. Eur Heart J. 2011;32:75–83.
    1. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175–82.
    1. Shepherd J, et al. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995;76(9):113–7.
    1. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.
    1. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the scandinavian simvastatin survival study. Lancet. 1994;344:1383–9.
    1. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.
    1. Pedersen TP, Faergeman O, Kastelein JP, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445.
    1. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial) Am J Cardiol. 2003;92:152–60.
    1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) JAMA. 2001;285:2486–97.
    1. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil. 2007;14(2):1–40.
    1. Clearfield MB, Amerena J, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hyperc holesterolemia—Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR.) Trials. 2006;7:35.
    1. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID Study. JAMA. 2006;295:1556–65.
    1. Crouse JR, 3rd, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR Study. JAMA. 2007;297:1344–1353.
    1. Takayama T, Hiro T, Yamagishi M, et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: The COSMOS Study. Circ J. 2007;71:271–5.
    1. Nicholls SJ, Ballantayne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87.
    1. Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis In Myocardial Infarction 22) Sub study. J Am Coll Cardiol. 2009;54:2290–5.
    1. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285:1711–8.
    1. Lablanche JM, Danchin N, Farnier M, et al. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design. Arch Cardiovasc Dis. 2008;101:399–406.
    1. Hall AS, Jackson BM, Farrin AJ, et al. A randomised controlled trial of simvastatin versus rosuvastatin in patients with acute myocardial infarction: The Secondary Prevention of Acute Coronary Events—Reduction of Cholesterol to Key European Targets (SPACE ROCKET) Trial. Eur J Cardiovasc Prev Rehabil. 2009;16:712–21.
    1. Mora S, Glynn RJ, Hsia J, et al. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. Circulation. 2010;121:1069–77.
    1. Glynn RJ, Koenig W, Nordestgaard BG, et al. Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average lowdensity lipoprotein cholesterol levels: exploratory analysis of a randomized trial. Ann Intern Med. 2010;152:488–96.
    1. Ridker PM, MacFadyen J, Cressman M, et al. Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention-an Intervention Trial Evaluating Rosuvastatin) trial. J Am Coll Cardiol. 2010;55:1266–73.
    1. Fellstrom BC, Jardine AG, Schmieder RE, et al. for the AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395–407.
    1. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–48.
    1. Baigent C, Landray MJ, Reith C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181–92.
    1. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) Clin Sci (Lond) 2001;101:671–9.
    1. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997;20:614–20.
    1. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (_2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dL) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study) Am J Cardiol. 2007;100:1245–8.
    1. Wolffenbuttel BH, Franken AA, Vincent HH on behalf of the Dutch CORALL Study Group. Cholesterol-lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes—CORALL study. J Intern Med. 2005;257:531–9.
    1. Berne C, Siewert-Delle A on behalf of the URANUS investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: results from the URANUS study. Cardiovasc Diabetol. 2005;4:7.
    1. Faergeman O, Hill L, Windler E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia: results from the ECLIPSE study. Cardiology. 2008;111(4):219–28.
    1. Bo M, Nicolello MT, Fiandra U, et al. Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs. simvastatin. Nutr Metab Cardiovasc Dis. 2001;11:17–24.
    1. Gagne C, Gaudet D, Bruckert E Ezetimibe Study Group. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469–75.
    1. Kjekshus J, Apetrei E, Barrios V, et al. for the CORONA Group. Rosuvastatin in older patients with systolic heart failure. New Eng J Med. 2007;357:2248–61.
    1. GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double blind, placebo-controlled trial. Lancet. 2008;372:1231–9.
    1. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet. 2004;363:369–370.
    1. Avis HJ, Hutten BA, Gagné C, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. Journal of the American College of Cardiology. 2010;55:1121–6.
    1. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. New Eng J Med. 2006;355:549–69.
    1. Gazzard BG, Anderson J, Babiker A, et al. BHIVA Treatment Guidelines Writing Group. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy. HIV Medicine. 2008;9:563–608.
    1. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clinical Pharmacokinetics. 2002;41:434–70.
    1. Ray GM. Antiretroviral and statin drug-drug interactions. Cardiology Reviews. 2009;17:44–7.
    1. Calza L, Manfredi R, Colangeli V, et al. Rosuvastatin, Pravastatin, and Atorvastatin for the Treatment of Hypercholesterolaemia in HIV-Infected Patients. Receiving Protease Inhibitors Current HIV Research. 2008;6:572–8.
    1. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales:population based cohort study using the QResearch database. BMJ. 2010;340:c2197.
    1. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
    1. Gadarla M, Kearns AK, Thompson PD. Efficacy of Rosuvastatin (5 mg and 10 mg) Twice a Week in Patients Intolerant to Daily Statins. Am J Cardiol. 2008;101:1747–8.
    1. Backes JM, Moriarty PM, Ruisinger JF, et al. Effects of Once Weekly Rosuvastatin Among Patients With a Prior Statin Intolerance. Am J Cardiol. 2007;100:554–5.
    1. Reddy KJ, Singh M, Batsell R, et al. R. Efficacy of Combination Drug Pulse Therapy in Maintaining Lipid Levels in Patients Intolerant of Daily Statin Use. J Clin Hypertens. 2009;11:766–8.
    1. Jones PH, Davidson MH, Kashyap ML, et al. Efficacy and safety of ABT- 335 (fenofibric acid) in combination with rosuvastatin in patients with mixed hyperlipidaemia: A phase 3 study. Atherosclerosis. 2009;201:208–15.
    1. Durrington PN, Tuomilehto J, Hamann A, et al. Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Research and Clinical Practice. 2004;64:137–51.
    1. Strain JD, Farver DK, Clem JR. A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate therapy. Clinical Pharmacology: Advances and Applications. 2010;2:95–104.
    1. EXPLORER Study Investigators. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER Study) Am J Cardiol. 2007;99:673–80.
    1. Bell DSH, O’Keefe JH. Rediscovering bile acid sequestrants. Diab Obes Metab. 2009;11:1114–21.
    1. Benner JS, Smith TW, Klingman D, et al. Cost-Effectiveness of Rosuvastatin Compared with Other Statins from a Managed Care Perspective. Value in Health. 2005;8:618–28.
    1. Bailey KM, Romaine SPR, Jackson BM, et al. Hepatic Metabolism and Transporter Gene Variants Enhance Response to Rosuvastatin in Patients With Acute Myocardial Infarction/Clinical Perspective: The GEOSTAT-1 Study. Circ Cardiovasc Genet. 2010;3:276–85.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj